Wordt geladen...
SAT-500 Response to Tocilizumab Retreatment in Refractory Thyroid Eye Disease
Background: The current standard of care for moderate to severe thyroid eye disease (TED) is intravenous methylprednisolone (IVMP), though alternative immunosuppressive options are emerging. In a recent randomized trial, Tocilizumab (TCZ), an anti-IL-6 receptor antibody, demonstrated improved effica...
Bewaard in:
Gepubliceerd in: | J Endocr Soc |
---|---|
Hoofdauteurs: | , , , , |
Formaat: | Artigo |
Taal: | Inglês |
Gepubliceerd in: |
Oxford University Press
2020
|
Onderwerpen: | |
Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7207507/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.1316 |
Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|